An interventional study of Biliary sphincterotomy in Acute Pancreatitis Due to Gallstones and Acute Pancreatitis, sponsored by Hospital General Universitario de Alicante. Enrolling by invitation at 5 sites in Spain. Per ClinicalTrials.gov, last updated 2025-01-01.
Sponsored by Hospital General Universitario de Alicante · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Pancreatitis with a site in Spain — 5 open to participants now, 5 under way, 1 of them phase 3. Pancreatitis · Spain.
Among the 21 studies in Pancreatitis with a site in Spain, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 with no phase, and was the 20th registered.
558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.
Browse Pancreatitis studies →5 of the 21 studies in Pancreatitis with a site in Spain are open now. Recruiting first, the newest first:
Hospital Universitari de Bellvitge · Sites in Spain
Ages 18–80
CytoSorbents, Inc · Sites in Spain, Austria, Germany and 3 more countries
Hospital General Universitario de Alicante · Sites in Spain
Ages 18+
University Hospital Virgen de las Nieves · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 126 is above the median of 100 across 349 interventional studies indexed under Pancreatitis.
Median enrollment 249 across the 13 interventional studies, 463 across the 8 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 21 have an industry lead sponsor. The 10 most frequent:
Hospital General Universitario de Alicante is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
Hospital General Universitario de Alicante has 3 studies filed under Pancreatitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Pancreatitis with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04924868Phase 3Hospital General Universitario de AlicanteUrsodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis | 2027-07-01 |
| NCT06409741Hospital General Universitario de AlicantePrEveNtion of Biliary Events After Acute Pancreatitis in NonSUrgicaL PAtients: PENINSULA Trial | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Pancreatitis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute pancreatitis (AP) is a common condition and its main etiology is biliary. Cholecystectomy is the standard preventive treatment for recurrence of AP after admission. However, due to an increasingly older population and increased patient comorbidity, it is not always a possible option these days. If cholecystectomy is not performed, there is a significant risk for a recurrence of a biliopancreatic event (pancreatitis, biliary colic, choledocholithiasis, cholecystitis or cholangitis) of around 50% in the first year. This can lead to further episodes of pain, patient readmissions, and a reduced quality of life. Additionally, frequent readmissions can create a high cost burden on the health system. Currently, certain clinical guidelines propose biliary sphincterotomy as an alternative for patients in whom surgery is not feasible. However, this recommendation is based on retrospective studies with small sample size and the adherence to this recommendation is very low (12-23%).
The goal of this clinical trial is to evaluate the recurrence of biliopancreatic events in the first year after admission for an acute biliary pancreatitis episode in patients that are not suitable for surgery. The main question it aims to answer is:
Does biliary sphincterotomy prevent biliopancreatic event recurrence in non surgical patients after an episode of biliary acute pancreatitis?
Researchers will compare biliary sphincterotomy vs conservative treatment to see if there is a reduction in biliopancreatic events during the first year after admission for acute pancreatitis in non surgical patients.
Participants will be randomized to conservative treatment or biliary sphincterotomy and will be followed up for one year at 1 month, 6 months and 12 months to evaluate recurrence of BPE, readmissions, quality of life and mortality. Security of the technique will also be assessed in this specific population.
Our working hypothesis is that endoscopic treatment with biliary sphincterotomy will reduce the number of biliopancreatic events compared to conservative treatment in patients with non-operable biliary acute pancreatitis (AP) due to a high surgical risk or in those patients who refuse surgery.
The primary aim is to assess the recurrence of the combined variable of biliopancreatic events (BPE) (biliary colic, cholangitis, choledocholithiasis, acute cholecystitis or AP) of the endoscopic sphincterotomy strategy during the follow-up time after diagnosis of AP of biliary origin in inoperable patients with respect to conservative treatment.
This is a randomized, multicenter, open-label, nationwide, intention-to-treat clinical trial. Patients will be randomized 1:1 to the two treatment groups stratified by center and AP severity.
Centers considered to participate as collaborators centers will need to have an endoscopy unit with ERCP availability that perform more than 150 ERCPs/year, and endoscopists trained in this technique. Patient inclusion and exclusion criteria is specified in a specific section of the protocol.
For the inclusion of patients, after diagnosis of biliary AP (BAP), and having ruled cholecystectomy as a possibility for the patient because of high surgical risk (after evaluation by surgery or anesthesia) or patient's refusal to undergo cholecystectomy, the absence of choledocholithiasis will be confirmed by MRCP or EUS.
If the patient fulfills these requirements, in addition to all the previous inclusion criteria and none of the exclusion criteria, and agrees to participate in the study and signs the informed consent the patient will be included and randomized.
This randomization will be carried out in each of the collaborating centers and the patient will be assigned to a treatment group following the random assignment method.
The randomization of patients to each of the treatment groups will be carried out centrally by the REDCap software; REDCap is a program that offers an online electronic data collection notebook. It will be stratified by center and by severity of BAP (mild, moderate or severe according to the Revised Atlanta Classification).
Patients will be randomized to receive ERCP biliary sphincterotomy or conservative management. 63 patients will be allocated to each group. An interim safety analysis is proposed, which will be evaluated by an independent committee of 3 persons, with experience in complications associated with ERCP and knowledge of biliopancreatic pathology, once 50% of the sample reaches 6 months of follow-up. In the event that in this first analysis the risks of treatment outweigh the benefits, according to the decision of the safety committee, the study could be stopped. Also, in the event that at this point there are statistically significant differences in favor of treatment by biliary sphincterotomy with respect to the primary outcome, recruitment can be stopped and the study stopped early.
In the group assigned to receive endoscopic treatment, ERCP for biliary sphincterotomy will be performed during the index admission for acute pancreatitis, prior to discharge or up till one month from discharge.
The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center.
For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary. The type of papilla, cannulation attempts, time to biliary cannulation and the technique(s) used will be recorded. Possible adverse effects will be recorded. If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be counted as a technical failure, maintaining the established clinical follow-up.
The inhospital management of patients with AP in the conservative treatment group, before and after randomization, will be under the care of their responsible physicians on the hospitalization wart at the corresponding collaboration center who will follow the management recommended by the clinical guidelines. Their discharge will be decided by their regular physician.
Periodic follow-up contacts will be made: at one month, at 6 months and at one year. Contacts may be made by face-to-face or telematic visits after consultation with the patient, especially if the patient is institutionalized or has severe mobility problems.
In these contacts, the following will be performed:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the group assigned to receive endoscopic treatment, ERCP for biliary sphincterotomy will be performed during the index admission for acute pancreatitis, prior to discharge or up till one month from discharge. The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center. For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary. If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be counted as a technical failure.
Procedure: Biliary sphincterotomy
Patients allocated to this group will be discharged without any intervention. The inhospital management of patients with AP in the conservative treatment group, before and after randomization, will be under the care of their responsible physicians on the hospitalization wart at the corresponding collaborating center who will follow the management recommended by the clinical guidelines. Their discharge will be decided by their regular physician. Patients will be evaluated at one month, six months and one year and both clinical variables (clinical BPE recurrence) and quality of life will be assessed (quality of life by a survey- EORTC QLQ-C30,
ERCP for biliary sphincterotomy will be performed during index admission for acute pancreatitis, prior to discharge or up till one month from discharge. The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center. For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary. If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be it will be counted as a technical failure, maintaining the established clinical follow-up.
Biliopancreatic events (BPE)
The primary aim is to assess the recurrence of the combined variable of biliopancreatic events (biliary colic, cholangitis, choledocholithiasis, acute cholecystitis or AP) of the endoscopic sphincterotomy strategy during the follow-up time after diagnosis of AP of biliary origin in inoperable patients with respect to conservative treatment.
Time frame: From enrollment until 12 months after
Time to recurrence of BPE
Time in days to recurrence of biliopancreatic events between both groups
Time frame: From enrollment until 12 months after
Recurrence of each of the variables that make up the combined variable BPE separately
To assess the recurrence of each of the variables that make up the combined variable BPE separately and compare them between groups (AP, cholangitis, choledocholithiasis, cholecystitis, biliary colic).
Time frame: From enrollment until 12 months after
Technical success of biliary sphincterotomy
Technical success will be defined as the achievement of biliary sphincterotomy defined by the endoscopist performing the procedure.
Time frame: From enrollment until one month after
Sphincterotomy related adverse events
To describe the complications associated with sphincterotomy and the management of these adverse events of patients included in the study with the AGREE scale of endoscopic adverse events (Classification of Adverse events GastRointEstinal Endoscopy). This classification of adverse events ranges from 0 (no adverse events) until 5 (death) due to complications related to the procedure.
Time frame: From enrollment until one month after
Emergency room visits (BPE related)
Number of visits to the emergency room due to a BPE
Time frame: From enrollment until 12 months after
Admission rate (BPE related)
To evaluate differences between admission rate in hospital between both groups related to BPE
Time frame: From enrollment until 12 months after
Admission rate (not BPE related)
Number of admissions (not directly associated to BPE) in hospital and comparison between both groups
Time frame: From enrollment until 12 months after
Emergency room visits (not BPE related)
Number of emergency room visits that do not require admission and are not specifically related to BPE
Time frame: From enrollment until 12 months after
Mortality at 30 days
Mortality at 30 days and comparison between both groups
Time frame: From enrollment until one month after
Hospital readmission at 30 days
Hospital admission at day 30 due to EBP or not related to EBP and comparison between both groups
Time frame: From enrollment until one month after
Mortality at one year
Evaluation of mortality at one year and comparison between both groups
Time frame: From enrollment until 12 months after
Index admission duration
Days of index admission due to AP and comparison between both groups
Time frame: From enrollment until one month after
Quality of life during follow-up
Quality of life will be assessed at every visit (1 month, 6 months and 12 months) with EORTC ( European Organization for Research and Treatment of Cancer ) Quality of Life Questionnaire C-30 and groups will be compared.The questionnaire is structured in 5 functional scales (physical functioning, activities of daily living, emotional functioning, cognitive functioning and social functioning), 3 symptom scales (fatigue, pain and nausea, vomiting), 1 global health status scale and, finally, 6 independent items (dyspnea, insomnia, anorexia, constipation, diarrhea and economic impact). Values between 1 and 4 (1: not at all, 2: a little, 3: quite a lot, 4: a lot) are assigned according to the patient's responses to the item, only items 29 and 30 are evaluated with scores from 1 to 7 (1: very bad, 7: excellent). The scores obtained are standardized and a score between 0 and 100 is obtained.
Time frame: From enrollment until 12 months after
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.
Of 92 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 31 months is close to that.
Counting every sponsor, half of 95 studies reached it within 32 months; a quarter within 23 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital General Universitario de Alicante